Candel Therapeutics Files Proxy Statement for Annual Meeting

TL;DR

Candel Therapeutics (CADL) proxy filed - shareholders vote on directors & auditors June 26.

AI Summary

Candel Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on May 30, 2024, for its annual meeting of stockholders scheduled for June 26, 2024. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and outcomes of the shareholder vote can significantly impact the company's future operations and stock performance.

Key Numbers

• DEF 14A — Filing Type (Definitive Proxy Statement)

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• 0001193125-24-150379 (filing_id) — Accession Number
• 20240530 (date) — Filing Date
• 20240626 (date) — Meeting Date

FAQ

Key Financial Figures

• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
• $0.01 — 5 shares of our common stock, par value $0.01 per share, outstanding on May 15, 2024,

Filing Documents

• d777600ddef14a.htm (DEF 14A) — 354KB
• g777600dsp038.jpg (GRAPHIC) — 123KB
• g777600dsp039.jpg (GRAPHIC) — 111KB
• 0001193125-24-150379.txt ( ) — 668KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS 36 REPORT OF THE AUDIT COMMITTEE 39 HOUSEHOLDING 40 STOCKHOLDER PROPOSALS 40 OTHER MATTERS 40 i Table of Contents CANDEL THERAPEUTICS, INC. 117 Kendrick St, Suite 450 Needham, MA 02494 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 26, 2024 This proxy virtually via the Internet at www.virtualshareholdermeeting.com/CADL2024, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the proxy card in order to attend the Annual Meeting. The board of directors of Candel Therapeutics, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms Candel, Candel Therapeutics, the Company, we, us, and our refer to Candel Therapeutics, Inc. The mailing address of our principal executive offices is Candel Therapeutics, Inc., 117 Kendrick St, Suite 450, Needham, MA 02494. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect. This proxy statement and our 2023 Annual Report to Stockholders for the fiscal year ended December 31, 2023, or the 2023 Annual Report, are first being made available to stockholders on or about May 30, 2024. We are an emerging growth company under applicable federal secu

: Gender Identity

Part I: Gender Identity Directors 3 6 1

: Demographic Background

Part II: Demographic Background African American or Black Alaskan Native or Native American Asian 1 Hispanic or Latinx 1 Native Hawaiian or Pacific Islander White 2 5 Two or More Races or Ethnicities LGBTQ+ Did Not Disclose Demographic Background 1 In addition to the information presented below regarding each of the nominees and continuing directors specific experience, qualifications, attributes and skills that our board of directors and our nominating and corporate governance committee considered in determining that he or she should serve as a director, we also believe that each of our directors has demonstrated business acumen, integrity and an ability to exercise sound judgment, as well as a commitment of service to our Company and our board of directors. Nominees for Election as Class III Director The following table identifies our director nominees, and sets forth their principal occupation and business experience during the last five years and age as of May 30, 2024. Name Positions and Offices Held with Candel Therapeutics, Inc. Director Since Age Nicoletta Loggia, Ph.D., R.Ph. Director 2023 56 Christopher Martell Director 2018 45 Diem Nguyen, Ph.D. Director 2021 52 Nicoletta Loggia, Ph.D., R.Ph. , has served as a member of

View Full Filing

View this DEF 14A filing on SEC EDGAR